31 May
2023
16:18 E.S.T.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Read more

24 May
2023
19:05 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 27, 2023

Read more

17 May
2023
14:00 E.S.T.

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

Read more

12 May
2023
19:12 E.S.T.

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Read more

11 May
2023
08:37 E.S.T.

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Read more

04 May
2023
14:49 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

Read more

02 May
2023
12:05 E.S.T.

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Read more

27 Apr
2023
10:01 E.S.T.

Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

Read more

24 Apr
2023
11:39 E.S.T.

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Read more

17 Apr
2023
02:00 E.S.T.

Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting

Read more